TPN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TPN (TPN).

How it works

Total parenteral nutrition (TPN) provides essential nutrients (carbohydrates, proteins, fats, electrolytes, vitamins, trace elements) to maintain metabolic homeostasis when enteral nutrition is not possible or sufficient. It supports anabolism, prevents catabolism, and corrects deficiencies.

What the body does with it

Metabolism	Metabolic pathways involve hepatic and peripheral tissues. Carbohydrates are metabolized via glycolysis and oxidative phosphorylation; proteins undergo hepatic deamination and transamination; lipids are cleared by lipoprotein lipase and oxidized; electrolytes and vitamins are utilized in various biosynthetic pathways.
Excretion	TPN components are metabolized and excreted via various routes. Amino acids are metabolized to urea (excreted renally) or incorporated into proteins. Dextrose is oxidized to CO2 and water (excreted via lungs and kidneys). Lipids are metabolized and stored; fatty acids are oxidized. Electrolytes and trace elements are primarily excreted renally. No single excretion route predominates; renal excretion accounts for ~50% of nitrogen waste, and CO2 is exhaled.
Half-life	Not applicable as a single entity; TPN is a composite. Individual components have variable half-lives: glucose ~2-4 hours, amino acids minutes to hours, lipids ~12-24 hours for triglycerides. Clinical context: continuous infusion maintains steady state.
Protein binding	Variable; amino acids are mostly unbound; lipids bind to lipoproteins; electrolytes like calcium are 40-50% bound to albumin; trace elements bind to specific transport proteins (e.g., transferrin for iron). Overall, no single value.
Volume of Distribution	Not applicable as a single entity. Individual components: glucose ~0.2 L/kg (ECF), amino acids ~0.5 L/kg (total body water), lipids ~0.1 L/kg (plasma). Clinical meaning: reflects distribution into body compartments.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate for electrolytes and glucose; amino acids and lipids act within hours as metabolic substrates.
Duration of Action	Duration is continuous during infusion; metabolic effects persist post-infusion (e.g., glucose regulation for 6-12 hours, lipid clearance 12-24 hours). Clinical note: TPN is a maintenance therapy, not a single-dose drug.

Classification & Brands

Dosing & administration

TPN (total parenteral nutrition) dosing is individualized. Typical adult: 1.0-2.0 g/kg/day amino acids, 1.0-2.0 g/kg/day lipids, and 5-15 g/day glucose (with insulin as needed). Infused via central line at 50-100 mL/hour initially, titrated to metabolic needs.

Dosage form	SUSPENSION
Renal impairment	GFR <30 mL/min: Reduce protein to 0.6-0.8 g/kg/day. GFR 30-50: 0.8-1.0 g/kg/day. GFR >50: Standard protein. Monitor electrolytes (K, Mg, P) closely and adjust per serum levels.
Liver impairment	Child-Pugh A: Use standard branched-chain amino acid (BCAA)-enriched formulas. Child-Pugh B: 70-80% of standard protein (0.8-1.0 g/kg/day) with BCAA. Child-Pugh C: 0.6-0.8 g/kg/day protein with BCAA, restrict lipids to 1 g/kg/day.
Pediatric use	Neonates: 2.0-4.0 g/kg/day amino acids, 0.5-3.0 g/kg/day lipids, glucose infusion rate starting 4-6 mg/kg/min. Infants/children: 1.5-3.0 g/kg/day protein, 2.0-4.0 g/kg/day lipids, titrate to growth and metabolic parameters.
Geriatric use	Elderly: Use 0.8-1.2 g/kg/day protein, 0.8-1.0 g/kg/day lipids. Monitor for fluid overload (start at 30-40 mL/hour), electrolyte disturbances, and glucose intolerance. Reduce glucose infusion rate if hyperglycemia occurs.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TPN (TPN).

Breastfeeding	TPN components are generally compatible with breastfeeding as they are nutrients normally present in human milk. No M/P ratio available. Use under medical supervision; monitor infant for metabolic disturbances if maternal TPN includes high glucose or lipid loads.
Teratogenic Risk	Total parenteral nutrition (TPN) is not a single drug but a formulation of nutrients. There is no evidence of teratogenicity; risks are associated with underlying maternal conditions and potential metabolic complications (e.g., hyperglycemia, electrolyte imbalances). No known fetal defects from TPN components.

Warnings & precautions

■ FDA Black Box Warning

Risk of infections (catheter-related bloodstream infections), metabolic complications (hyperglycemia, hypoglycemia, electrolyte imbalances, refeeding syndrome), and hepatobiliary disorders (steatosis, cholestasis). Death may occur from improper preparation or administration.

Side Effect Profile

Serious Effects

Absolute Contraindications

Absolute: Known hypersensitivity to any component; unstable metabolic conditions (severe acidosis, hyperlipidemia, uremia, galactosemia); severe pancreatitis with hypertriglyceridemia; unstable hemodynamics. Relative: Renal/hepatic failure (requires dose adjustment), severe electrolyte disorders.

Clinical Precautions

Precautions

Monitor for infection, metabolic abnormalities (hyperglycemia, hypoglycemia, electrolyte disturbances, hypertriglyceridemia), refeeding syndrome, hepatobiliary complications (elevated liver enzymes, steatosis), thrombophlebitis, and fluid overload. Adjust composition based on renal/hepatic function.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TPN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TPN (TPN).

How it works

What the body does with it

Metabolism	Metabolic pathways involve hepatic and peripheral tissues. Carbohydrates are metabolized via glycolysis and oxidative phosphorylation; proteins undergo hepatic deamination and transamination; lipids are cleared by lipoprotein lipase and oxidized; electrolytes and vitamins are utilized in various biosynthetic pathways.
Excretion	TPN components are metabolized and excreted via various routes. Amino acids are metabolized to urea (excreted renally) or incorporated into proteins. Dextrose is oxidized to CO2 and water (excreted via lungs and kidneys). Lipids are metabolized and stored; fatty acids are oxidized. Electrolytes and trace elements are primarily excreted renally. No single excretion route predominates; renal excretion accounts for ~50% of nitrogen waste, and CO2 is exhaled.
Half-life	Not applicable as a single entity; TPN is a composite. Individual components have variable half-lives: glucose ~2-4 hours, amino acids minutes to hours, lipids ~12-24 hours for triglycerides. Clinical context: continuous infusion maintains steady state.
Protein binding	Variable; amino acids are mostly unbound; lipids bind to lipoproteins; electrolytes like calcium are 40-50% bound to albumin; trace elements bind to specific transport proteins (e.g., transferrin for iron). Overall, no single value.
Volume of Distribution	Not applicable as a single entity. Individual components: glucose ~0.2 L/kg (ECF), amino acids ~0.5 L/kg (total body water), lipids ~0.1 L/kg (plasma). Clinical meaning: reflects distribution into body compartments.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate for electrolytes and glucose; amino acids and lipids act within hours as metabolic substrates.
Duration of Action	Duration is continuous during infusion; metabolic effects persist post-infusion (e.g., glucose regulation for 6-12 hours, lipid clearance 12-24 hours). Clinical note: TPN is a maintenance therapy, not a single-dose drug.

Classification & Brands

Dosing & administration

Dosage form	SUSPENSION
Renal impairment	GFR <30 mL/min: Reduce protein to 0.6-0.8 g/kg/day. GFR 30-50: 0.8-1.0 g/kg/day. GFR >50: Standard protein. Monitor electrolytes (K, Mg, P) closely and adjust per serum levels.
Liver impairment	Child-Pugh A: Use standard branched-chain amino acid (BCAA)-enriched formulas. Child-Pugh B: 70-80% of standard protein (0.8-1.0 g/kg/day) with BCAA. Child-Pugh C: 0.6-0.8 g/kg/day protein with BCAA, restrict lipids to 1 g/kg/day.
Pediatric use	Neonates: 2.0-4.0 g/kg/day amino acids, 0.5-3.0 g/kg/day lipids, glucose infusion rate starting 4-6 mg/kg/min. Infants/children: 1.5-3.0 g/kg/day protein, 2.0-4.0 g/kg/day lipids, titrate to growth and metabolic parameters.
Geriatric use	Elderly: Use 0.8-1.2 g/kg/day protein, 0.8-1.0 g/kg/day lipids. Monitor for fluid overload (start at 30-40 mL/hour), electrolyte disturbances, and glucose intolerance. Reduce glucose infusion rate if hyperglycemia occurs.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TPN (TPN).

Breastfeeding	TPN components are generally compatible with breastfeeding as they are nutrients normally present in human milk. No M/P ratio available. Use under medical supervision; monitor infant for metabolic disturbances if maternal TPN includes high glucose or lipid loads.
Teratogenic Risk	Total parenteral nutrition (TPN) is not a single drug but a formulation of nutrients. There is no evidence of teratogenicity; risks are associated with underlying maternal conditions and potential metabolic complications (e.g., hyperglycemia, electrolyte imbalances). No known fetal defects from TPN components.